This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Pharma Stock Roundup: EU Nod for AZN, JNJ & Others, PFE COVID Jab Effective in Kids
by Kinjel Shah
European Commission authorizes a booster dose of AstraZeneca's (AZN) COVID-19 vaccine and approves Merck (MRK) and Roche's (RHHBY) oncology drugs for expanded use.
Roche (RHHBY) Gets EC Approval for Polivy Combination in DLBCL
by Zacks Equity Research
Roche's (RHHBY) Polivy combination receives the European Commission's approval for patients with previously untreated diffuse large B-cell lymphoma.
Global Blood (GBT) Thrives on Oxbryta, Overdependence a Woe
by Zacks Equity Research
Global Blood's (GBT) Oxbryta is approved for treating sickle cell disease. The recent label expansion nod to Oxbryta is a positive. However, sole dependence on Oxbryta for growth is a concern.
Amgen (AMGN) Ahead of Industry This Year So Far: What's Next?
by Zacks Equity Research
Amgen's (AMGN) key drugs like Prolia, Repatha, Xgeva and biosimilars are driving sales. Amgen is also rapidly advancing its robust pipeline of early and late-stage assets.
Seagen (SGEN) Posts Positive Data from New Study on Tukysa
by Zacks Equity Research
Seagen (SGEN) reports favorable data on the pivotal phase II MOUNTAINEER study evaluating Tukysa in combination with Herceptin for treating HER2-positive metastatic colorectal cancer.
ImmunoGen (IMGN) Ovarian Cancer Drug BLA Gets Priority Review
by Zacks Equity Research
ImmunoGen (IMGN) gets priority review from the FDA for the BLA seeking approval for its lead candidate, mirvetuximab soravtansine, for treating platinum-resistant ovarian cancer.
5 Reasons Why You Should Add Halozyme (HALO) to Your Portfolio
by Zacks Equity Research
We provide five reasons, which make Halozyme (HALO) a good investment option in 2022.
Pharma Stock Roundup: PFE's Biohaven Buyout Offer, BAYRY's Q1 Earnings Update
by Kinjel Shah
Pfizer (PFE) is set to buy migraine drugmaker, Biohaven Pharmaceuticals for $11.6 billion. Bayer (BAYRY) beats Q1 earnings and sales expectations.
Roche (RHHBY) Phase III NSCLC Study Disappoints, Stock Down
by Zacks Equity Research
Roche (RHHBY) stock declines as the late-stage study evaluating tiragolumab plus Tecentriq fails to meet its co-primary endpoint of progression-free survival.
Epizyme (EPZM) Q1 Earnings Miss, Revenues Lag Estimates
by Zacks Equity Research
Epizyme (EPZM) posts a wider-than-expected loss for the first quarter. Revenues also miss estimates. EPZM has multiple pipeline readouts on track for this year.
Halozyme (HALO) Q1 Earnings Miss, Royalties Aid Y/Y Revenues
by Zacks Equity Research
Halozyme (HALO) first-quarter earnings and sales miss estimates. Strong demand for the partnered drug, subcutaneous Darzalex, boosts the top line.
ImmunoGen (IMGN) Q1 Earnings and Sales Outpace Estimates
by Zacks Equity Research
ImmunoGen (IMGN) reports a narrower-than-expected loss for first-quarter 2022. It also beats revenue estimates.
Prothena (PRTA) Q1 Earnings Beat, Pipeline Progress in Focus
by Zacks Equity Research
Prothena beats on earnings and revenues in the first quarter of 2022. The company's progress with its AD pipeline is encouraging.
Puma Biotech (PBYI) Q1 Earnings Beat, Nerlynx Sales Fall Y/Y
by Zacks Equity Research
Puma Biotech (PBYI) Q1 loss narrows while sales come in line with estimates. PBYI's stock declines in the after-market trading session following the news.
Sarepta (SRPT) Q1 Earnings Beat, DMD Drugs' Sales Robust
by Zacks Equity Research
Strong demand for Sarepta's (SRPT) DMD drugs boosts its top line in the first quarter. Stock up in after-market trading.
Blueprint Medicines (BPMC) Q1 Loss in Line, Revenues Top Mark
by Zacks Equity Research
Blueprint Medicines' (BPMC) earnings meet estimates while revenue beat the same for the first quarter of 2022. Stock up.
Regeneron (REGN) Q1 Earnings Beat, COVID Antibody Sales Affected
by Zacks Equity Research
Regeneron (REGN) beats on Q1 earnings and sales record year-over-year growth on the solid performance of Dupixent and Eylea.
Biogen (BIIB) Q1 Earnings Miss, Aduhelm Setback Leads to Rejig
by Zacks Equity Research
Biogen (BIIB) misses first-quarter estimates for earnings but beats the same for sales. Following no medicare beneficiary access to Aduhelm, Biogen initiates a cost-savings program.
Seagen's (SGEN) Q1 Earnings & Revenues Surpass Estimates
by Zacks Equity Research
Seagen (SGEN) reports narrower-than-expected loss in the first quarter of 2022 while its revenues beat estimates.
Amgen's (AMGN) Q1 Earnings Top, Stock Down on IRS Tax Dispute
by Zacks Equity Research
Amgen (AMGN) beats Q1 estimates for earnings and sales. The stock declines on the announcement of litigation and tax dispute with the IRS.
Will Biogen (BIIB) Succeed in Beating Q1 Earnings Estimates?
by Zacks Equity Research
Biogen's (BIIB) multiple sclerosis revenues have been declining since the past few quarters. It is unlikely that MS sales have improved in the first quarter.
Novartis (NVS) Beats on Q1 Earnings, Sandoz Posts Growth
by Zacks Equity Research
Novartis (NVS) beats on earnings in the first quarter but sales lag expectations. Generic Sandoz business returns to growth.
Is a Beat Likely for AbbVie (ABBV) This Earnings Season?
by Zacks Equity Research
AbbVie's (ABBV) first-quarter results are expected to reflect the impact of strong demand for immunology drugs, aesthetics and cosmetics products. Investors are likely to focus on any update related to Humira LOE.
Roche's (RHHBY) Q1 Sales Grow on COVID-19 Tests, New Drugs
by Zacks Equity Research
Roche (RHHBY) performance in the first quarter was encouraging, driven by demand for COVID-19 tests and contribution from newer drugs.
Halzoyme (HALO) Up 8.3% YTD: Will It Continue to Trend Higher?
by Zacks Equity Research
Halozyme's (HALO) revenues are driven by strong demand for new partnered drugs. Restructuring initiatives are boosting margins. Robust revenue growth is expected to continue in 2022.